Yong‐Gil Kim
YOU?
Author Swipe
View article: Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data
Machine learning-based prediction of response to Janus kinase inhibitors in patients with rheumatoid arthritis using clinical data Open
Objective Rheumatoid arthritis (RA) is a chronic inflammatory disease with considerable heterogeneity in treatment response, leaving many patients unable to achieve remission or low disease activity. We aimed to develop a machine learning …
View article: Age-Specific Risk Factors for Cancer in a Long-Term Korean Cohort of Patients with Ankylosing Spondylitis Treated with TNF Inhibitors
Age-Specific Risk Factors for Cancer in a Long-Term Korean Cohort of Patients with Ankylosing Spondylitis Treated with TNF Inhibitors Open
Background/Objectives: Tumor necrosis factor (TNF) inhibitors are widely used in ankylosing spondylitis (AS), but data on cancer risk in this young population remain limited. We aimed to identify factors associated with cancer during TNF i…
View article: Association Between Adalimumab Dosing Interval and Uveitis Recurrence in Patients with Ankylosing Spondylitis
Association Between Adalimumab Dosing Interval and Uveitis Recurrence in Patients with Ankylosing Spondylitis Open
Background/Objectives: Ankylosing spondylitis (AS) is a chronic inflammatory disease frequently associated with acute uveitis (AU). Adalimumab, a monoclonal tumor necrosis factor (TNF) inhibitor, is widely used to manage AS and AU. While b…
View article: Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease
Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease Open
Background Idiopathic inflammatory myositis (IIM) frequently coexists with interstitial lung disease (ILD), significantly impacting morbidity and mortality. Spontaneous pneumomediastinum, a complication of myositis-associated ILD, remains …
View article: Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis
Renal safety of Long-Term Non-steroidal Anti-inflammatory drugs use in patients with ankylosing spondylitis Open
Objectives We investigate the renal safety of long-term non-steroidal anti-inflammatory drugs (NSAIDs) exposure in patients with ankylosing spondylitis (AS). Methods We analyzed electronic medical records from Asan Medical Center (AMC) and…
View article: Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study
Risk of ischemic stroke associated with anti-rheumatic agents in patients with rheumatoid arthritis: A nationwide population-based case-control study Open
Introduction Patients with rheumatoid arthritis (RA) face a significantly higher risk of major adverse cardiovascular events, including stroke, due to the pivotal role of inflammation in atherosclerosis and thrombosis. Various anti-rheumat…
View article: Risk of acute myocardial infarction associated with antirheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study
Risk of acute myocardial infarction associated with antirheumatic agents in patients with rheumatoid arthritis: a nationwide population-based case-control study Open
The study demonstrates a significant association between the current and long-term use of glucocorticoids and leflunomide and an increased risk of AMI in patients with RA. These findings underscore the importance of careful consideration o…
View article: Anti-protein phosphatase magnesium-dependent 1A-IgM levels in patients with active ankylosing spondylitis: a potential biomarker
Anti-protein phosphatase magnesium-dependent 1A-IgM levels in patients with active ankylosing spondylitis: a potential biomarker Open
Background Ankylosing spondylitis (AS) has been known to have auto-inflammatory nature; hence, the efficacy of autoantibodies is low. However, studies on autoantibodies are ongoing, with some studies showing associations. Previous studies …
View article: Lupus flare and recurrent lupus nephritis following kidney transplantation in patients with lupus nephritis
Lupus flare and recurrent lupus nephritis following kidney transplantation in patients with lupus nephritis Open
Background Clinical manifestations and risk factors associated with systemic lupus erythematosus (SLE) flares, including recurrent lupus nephritis (LN), in patients with LN who undergo kidney transplantation have been unclear. Methods Kidn…
View article: Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies
Expression of CD163 and major histocompatibility complex class I as diagnostic markers for idiopathic inflammatory myopathies Open
Background To develop an inflammation-related immunohistochemistry marker-based algorithm that confers higher diagnostic ability for idiopathic inflammatory myopathies (IIMs) than IIM-related histopathologic features. Methods Muscle biopsy…
View article: Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease
Clinical impact of pneumomediastinum in patients with myositis-associated interstitial lung disease Open
Background: Idiopathic inflammatory myositis (IIM) frequently coexists with interstitial lung disease (ILD), significantly impacting morbidity and mortality. Spontaneous pneumomediastinum, a complication of myositis-associated ILD, remains…
View article: Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics
Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics Open
Background To assess the drug survival and change of disease activity using a second Janus kinase inhibitor (JAKi) after failure to a JAKi and subsequent biologic disease-modifying anti-rheumatic drugs (bDMARDs) in patients with difficult-…
View article: Prevalence and Risk Factors of COVID-19 Reinfection in Patients with Rheumatoid Arthritis: A Retrospective Observational Study
Prevalence and Risk Factors of COVID-19 Reinfection in Patients with Rheumatoid Arthritis: A Retrospective Observational Study Open
In this retrospective cohort study of patients with RA with COVID-19 infection, approximately 12% of patients experienced reinfection without significant change in disease activity. Leflunomide use was associated with a higher risk of rein…
View article: Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids
Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids Open
Background/Aims: Systemic lupus erythematosus (SLE) responder index (SRI)-4 response has been achieved with belimumab treatment in patients with moderate disease activity in cornerstone clinical trials and following studies. However, most …
View article: The Expression of the Alpha7 Nicotinic Acetylcholine Receptor and the Effect of Smoking in Curdlan-Administered SKG Mice
The Expression of the Alpha7 Nicotinic Acetylcholine Receptor and the Effect of Smoking in Curdlan-Administered SKG Mice Open
Nicotine, an abundant molecule in tobacco, has immunomodulatory effects on inflammatory diseases, primarily due to the activation of alpha7 nicotinic acetylcholine receptor (α7 nAChR). We aim to evaluate the expression of the α7 nAChR+ cel…
View article: Urine SERPINC1/ORM1 as biomarkers for early detection of lupus nephritis in MRL-lpr mice
Urine SERPINC1/ORM1 as biomarkers for early detection of lupus nephritis in MRL-lpr mice Open
Background To evaluate the usefulness of urine SERPINC1 and ORM1 as biomarkers for early detection of lupus nephritis (LN). Methods Using proteomics, we screened for potential urine biomarkers that differentiate LN from systemic lupus eryt…
View article: Recovery and long-term renal outcome of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis who are on dialysis at presentation
Recovery and long-term renal outcome of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis who are on dialysis at presentation Open
Approximately 38% of AAV patients on dialysis discontinued dialysis, and the recovered patients had improved renal function without dialysis during longer follow-up. Patients with AAV on dialysis should be given the possibility of dialysis…
View article: Long-term renal outcomes of patients with non-proliferative lupus nephritis
Long-term renal outcomes of patients with non-proliferative lupus nephritis Open
Background/Aims: Although non-proliferative lupus nephritis (LN) (class I, II or V) has been considered as a less severe type of LN, data on long-term renal prognosis are limited. We investigated the long-term outcomes and prognostic facto…
View article: Relapse in patients with antineutrophil cytoplasmic antibody-associated vasculitis undergoing dialysis: a single-centre retrospective study in South Korea
Relapse in patients with antineutrophil cytoplasmic antibody-associated vasculitis undergoing dialysis: a single-centre retrospective study in South Korea Open
In patients with AAV undergoing dialysis, DAH and mean corticosteroid dose were significantly associated with relapse, highlighting the importance of close monitoring.
View article: LSO-003 Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice
LSO-003 Effects of progesterone-induced blocking factor 1 on the alleviation of lupus nephritis in MRL/lpr mice Open
Background Progesterone-induced blocking factor 1 (PIBF1), a protein produced by maternal lymphocytes upon exposure to progesterone during pregnancy, acts as an immunomodulator by suppressing several immune pathway cytokines including Th1-…
View article: LP-063 Clinical characteristics and outcomes of libman sacks endocarditis in patients with systemic lupus erythematosus
LP-063 Clinical characteristics and outcomes of libman sacks endocarditis in patients with systemic lupus erythematosus Open
Background Libman-Sacks (LS) endocarditis is one of the major cardiac involvement of systemic lupus erythematosus (SLE) and can manifest with neuropsychiatric events including stroke. However, data on the clinical features of LS endocardit…
View article: LSO-072 Comparison of COVID-19 vaccination with influenza vaccination in Korean patients with systemic lupus erythematosus: perception, adverse events, and flares from the CIVIL study
LSO-072 Comparison of COVID-19 vaccination with influenza vaccination in Korean patients with systemic lupus erythematosus: perception, adverse events, and flares from the CIVIL study Open
Background Vaccines are widely credited for their role in reducing the incidence and the severity of various infections. The aim of the COVID-19 and Influenza Vaccine In Lupus (CIVIL) study was to compare the perception and safety profile …
View article: LP-162 Prognostic factors for the chronic thrombocytopenia in systemic lupus erythematosus
LP-162 Prognostic factors for the chronic thrombocytopenia in systemic lupus erythematosus Open
Background Immune thrombocytopenia (ITP) is a common hematologic manifestation in systemic lupus erythematosus (SLE). Thrombocytopenia can persist for more than one year, which is defined as chronic thrombocytopenia. This study aimed to id…
View article: LP-176 SARS-CoV-2 antibody formation after COVID-19 vaccination in SLE patients treated with belimumab: single-center prospective observational study
LP-176 SARS-CoV-2 antibody formation after COVID-19 vaccination in SLE patients treated with belimumab: single-center prospective observational study Open
Background Patients with systemic lupus erythematosus (SLE) should be more proactive with the administration of the COVID-19 vaccine, as their systemic conditions are prone to developing severe outcomes. However, there are concerns that im…
View article: LP-116 To get, or not to get: risk and benefit of COVID-19 vaccine in Korean patients with systemic lupus erythematosus
LP-116 To get, or not to get: risk and benefit of COVID-19 vaccine in Korean patients with systemic lupus erythematosus Open
Background Although the safety profile of COVID-19 vaccines was shown to be acceptable in the clinical trials, risk and benefit of the vaccines in patients with systemic lupus erythematosus (SLE) are not known, as these patients have been …
View article: LP-137 Benefits of ANA screening for NPSLE in patients admitted to the department of psychiatry
LP-137 Benefits of ANA screening for NPSLE in patients admitted to the department of psychiatry Open
Background Neuropsychiatric systemic lupus erythematosus (NPSLE) presenting with mood disorder, headache, psychosis, and cognitive impairment appears within 1 year of SLE diagnosis in more than half of cases.1–2 Most studies have focused o…